NEW YORK, Aug. 21, 2015 /PRNewswire/ -- Tripp Levy PLLC, a
leading national securities law firm, announces that it is
investigating potential securities claims on behalf of investors of
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("Northwest" or the
"Company") resulting from allegations that Northwest may have
issued materially misleading business information to the investing
public.
On June 19, 2014, a report
published by the website TheStreet.com stated that, "The
prestigious MD Anderson Cancer Center issued a stern rebuke to
Northwest Biotherapeutics (NWBO) for making promotional,
unjustified claims about results from an ongoing clinical trial of
an experimental cancer vaccine known as DCVax-Direct." MD Anderson
Cancer Center is running the DCVax-Direct clinical trial with
funding from Northwest Biotherapeutics. On this news, shares
of Northwest fell $0.87 per share to
$8.04, or more than 10.37%, in
intraday trading on June 19,
2014.
On July 7, 2014, a report
published by the seekingalpha.com website stated that,
"Northwest Bio has been the subject of a massive promotional
campaign which has seen the stock price soar." And, "in some cases,
authors have used fictitious identities and fake credentials within
healthcare or finance. In fact they are simply paid writers."
On this news, shares of Northwest fell $0.52 per share to $6.62, or more than 7.28%, in intraday trading on
July 7, 2014.
On August 21, 2015, pre-market,
news broke that the Company's Phase 3 DCVax-L brain cancer
treatment clinical trial in Germany was temporarily halted. A reason is
yet to be provided, and Northwest is yet to address the issue
publicly. On this news, Northwest shares fell as much as
$0.88, or 9.91% during intraday
trading on August 21, 2015.
If you purchased shares of Northwest and have suffered a loss
from your investment in Northwest common stock and would like to
learn more about this investigation, including your ability to
potentially recover your losses, please contact us either by email
at contact@tripplevy.com or by telephone at (800) 511-7037 or visit
our website at
www.tripplevy.com/participate-in-an-action.
Tripp Levy PLLC is a leading national securities and shareholder
rights law firm representing both individual and institutional
shareholders and, along with its affiliate, have recovered billions
of dollars for shareholders. Tripp Levy PLLC is affiliated
with Milberg LLP. The National Law Journal has named Milberg
one of the "50 Elite Trial Lawyer Firms" and one of the "50 Leading
Plaintiff Firms in America."
Attorney advertising. Prior results do not indicate a
similar outcome
Tripp Levy PLLC
New York, New York
Toll free: 800-511-7037
International: 602-241-2841
Email: contact@tripplevy.com
www.tripplevy.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/northwest-biotherapeutics-alert-national-securities-law-firm-announces-investigation-of-potential-securities-claims-and-encourages-investors-with-losses-to-contact-law-firm-for-more-information-300131933.html
SOURCE Tripp Levy PLLC